All In Biotech

Drug Trial Radar · NCT05821933

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

An Open Single-arm Study to Evaluate the Safety, Tolerability, Efficacy of RC108 in Combination With Furmonertinib and Toripalimab in Patients With Advanced EGFR-mutated NSCLC Ib/II Study

Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

106

Planned (sponsor's estimate)

Start

Sep 7, 2023

Primary completion

Sep 1, 2025

Study completion Sep 1, 2026

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

an open, single-arm, multicenter phase Ib/II study

Conditions

  • NSCLC

Interventions

  • RC108Drug

    RC108 plus Furmonertinib and/or Toripalimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: up to 24 months
  2. Dose limiting toxicity (DLT)Time frame: 21-days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.